메뉴 건너뛰기
Liver International
Volumn 34, Issue 6, 2014, Pages
Risk factors for severe anaemia during telaprevir-based triple therapy: Is acquired renal dysfunction the missing link?
Author keywords

[No Author keywords available]
Indexed keywords

CREATININE; HEMOGLOBIN; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER; OLIGOPEPTIDE;
EID: 84902546665     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12510     Document Type: Letter
Times cited : (3)
References (4)
  • 1
    • 84904501123 scopus 로고    scopus 로고
    • Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy
    • doi: 10.1111/liv.12342. [Epub ahead of print]
    • Crismale JF, Martel-Laferrière V, Bichoupan K, et al. Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int 2013. doi: 10.1111/liv.12342. [Epub ahead of print]
    • (2013) Liver Int
    • Crismale, J.F.1    Martel-Laferrière, V.2    Bichoupan, K.3
  • 2
    • 84894876789 scopus 로고    scopus 로고
    • Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir
    • Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014; 59: 46-8.
    • (2014) Hepatology , vol.59 , pp. 46-48
    • Mauss, S.1    Hueppe, D.2    Alshuth, U.3
  • 3
    • 84898459645 scopus 로고    scopus 로고
    • Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
    • Karino Y, Ozeki I, Hige S, et al., et al. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hep 2014; 21: 341-7.
    • (2014) J Viral Hep , vol.21 , pp. 341-347
    • Karino, Y.1    Ozeki, I.2    Hige, S.3
  • 4
    • 84902543215 scopus 로고    scopus 로고
    • Increased ribavirin biodisponibility associated with telaprevir use in HCV patients treated with PEG-IFN/rib- avirin/telaprevir triple therapy
    • A (abstr.)
    • Bailly F, Pradat P, Maynard M, et al. Increased ribavirin biodisponibility associated with telaprevir use in HCV patients treated with PEG-IFN/rib- avirin/telaprevir triple therapy. Hepatology 2013; 58 (suppl. 4); 1125 A (abstr.)
    • (2013) Hepatology , vol.58 , Issue.SUPPL. 4 , pp. 1125
    • Bailly, F.1    Pradat, P.2    Maynard, M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.